|
A Study of the Effectiveness and Tolerability of Weekly Rifapentine/Isoniazid for Three Months Versus Daily Isoniazid for Nine Months for the Treatment of Latent Tuberculosis Infection Clinical Trials Information presented on Clinical Trials Search is not designed to be a substitute for certified medical advice, trips or professional assistance with a real medical doctor. We aren't docs. Always confer with your doctor about A Study of the Effectiveness and Tolerability of Weekly Rifapentine/Isoniazid for Three Months Versus Daily Isoniazid for Nine Months for the Treatment of Latent Tuberculosis Infection conditions. Clinical Trials Search.org is a website committed to listing clinical research studies in human subjects. A Study of the Effectiveness and Tolerability of Weekly Rifapentine/Isoniazid for Three Months Versus Daily Isoniazid for Nine Months for the Treatment of Latent Tuberculosis Infection Clinical research trials and A Study of the Effectiveness and Tolerability of Weekly Rifapentine/Isoniazid for Three Months Versus Daily Isoniazid for Nine Months for the Treatment of Latent Tuberculosis Infection health trials happen in many of cities across the US. A clinical trial or clinical study is a research project with human volunteer subjects. Clinical drug trials and pharmaceutical clinical trials generally measure the effectualness of new does drugs. The intention of the studies / projects is to figure out particular human healthcare questions. Clinical trials are a popular manner for doctors, government agencies, and private sector corporations to detect cures for all forms of circumstances, like A Study of the Effectiveness and Tolerability of Weekly Rifapentine/Isoniazid for Three Months Versus Daily Isoniazid for Nine Months for the Treatment of Latent Tuberculosis Infection. A Study of the Effectiveness and Tolerability of Weekly Rifapentine/Isoniazid for Three Months Versus Daily Isoniazid for Nine Months for the Treatment of Latent Tuberculosis Infection Clinical Trials and other clinical trials allow for volunteers to undergo medical treatment options before they are available to the general public. Most times the subjects get treatment for free of charge, and occasionally they are paid for their time. Occasionally there is a cost for a A Study of the Effectiveness and Tolerability of Weekly Rifapentine/Isoniazid for Three Months Versus Daily Isoniazid for Nine Months for the Treatment of Latent Tuberculosis Infection clinical trial. Subjects frequently get the best healthcare possible for their A Study of the Effectiveness and Tolerability of Weekly Rifapentine/Isoniazid for Three Months Versus Daily Isoniazid for Nine Months for the Treatment of Latent Tuberculosis Infection condition. Hazards are a reality, however, and could include more or frequent mD visits, health risks (possibly life-jeopardizing), and/or the treatment being ineffectual. Trials are federally regulated with exacting guidelines to protect clinical trials patients.
|
|
|
|
|
|
|
Home > "A" Clinical Trials Conditions > A Study of the Effectiveness and Tolerability of Weekly Rifapentine/Isoniazid for Three Months Versus Daily Isoniazid for Nine Months for the Treatment of Latent Tuberculosis Infection A Study of the Effectiveness and Tolerability of Weekly Rifapentine/Isoniazid for Three Months Versus Daily Isoniazid for Nine Months for the Treatment of Latent Tuberculosis Infection
A Study of the Effectiveness and Tolerability of Weekly Rifapentine/Isoniazid for Three Months Versus Daily Isoniazid for Nine Months for the Treatment of Latent Tuberculosis Infection
For Condition: Tuberculosis
Status: Recruiting
Sponsor(s): Centers for Disease Control and Prevention , Department of Veterans Affairs
Synopsis: The primary objective of this open-label Phase III clinical trial is to compare the effectiveness of a three-month (12-dose) regimen of weekly rifapentine and isoniazid (3RPT/INH) to the effectiveness of a nine-month (270-dose) regimen of daily isoniazid (9INH). This trial will be conducted among high-risk tuberculin skin-test reactors, including children and HIV-infected persons, who require treatment of latent infection (TLI) to prevent tuberculosis (TB). The 3RPT/INH regimen will be given under direct observation and the 9INH regimen will be self-administered. Secondary Objective: Compare the rates of drug discontinuation due to adverse drug reactions associated with 3RPT/INH and 9INH. Compare the rates of drug discontinuation for any reason associated with 3RPT/INH and 9INH. Compare the rates of any grade 3, 4, or 5 drug toxicity associated with 3RPT/INH and 9INH. Compare treatment completion rates of 3RPT/INH and 9INH. Compare the efficacy (i.e., among persons who complete study-phase therapy) of 3RPT/INH and 9INH. Compare the effectiveness and tolerability of 3RPT/INH and 9INH in HIV-infected persons. Compare the effectiveness and tolerability of 3RPT/INH and 9INH in children < 18 years old. Compare the rates of methadone withdrawal associated with 3RPT/INH and 9INH among persons concomitantly receiving methadone. Describe patterns of antibiotic resistance among M. tuberculosis isolates in patients who develop TB despite treatment of latent infection.
Details:
Eligibility:
Study Type: Interventional, Treatment, Open Label, Efficacy Study
Minimum Age/Maximum Age: /
Genders: Both
Protocol Entry Criteria: - High-risk tuberculin skin-reactors requiring treatment of latent infection to prevent TB
Total Enrollment:
Location and Contact Information:
Audi L. Murphy VA Hospital *Recruiting*
San Antonio, Texas, 78284
United States
Recruiting Marc Weiner 210-617-5111
New York University School of Medicine *Recruiting*
New York City, New York, 10016
United States
Recruiting William Rom 212-263-6479
Carolinas Medical Center *Recruiting*
Charlotte, North Carolina, 28203
United States
Recruiting James Horton 704-355-3165
University of North Texas Health Science Center *Recruiting*
Ft. Worth, Texas, 76107-2699
United States
Recruiting Stephen Weis 817-871-7262
Montreal Chest Institute McGill University *Recruiting*
Montreal, Quebec, H2X 2P4Pq Canada
Canada
Recruiting Richard Menzies 514-398-8122
Thomas Street Clinic *Recruiting*
Houston, Texas, 77009
United States
Recruiting Christopher Lahart 713-793-4083
LA County/USC Medical Center *Recruiting*
Los Angeles, California, 90033
United States
Recruiting Brenda Jones 323-343-8300
Denver Department of Public Health and Hospitals *Recruiting*
Denver, Colorado, 80204
United States
Recruiting Randall Reves 303-436-7297
Columbia University/Presbyterian Medical Center *Recruiting*
New York City, New York, 10032
United States
Recruiting Neil Schluger 212-305-9817
Duke University Medical Center *Recruiting*
Durham, North Carolina, 34222
United States
Recruiting Carol Dukes Hamilton 919-684-3279
Washington, D.C. VAMC *Recruiting*
Washington D.C., District of Columbia, 20422
United States
Recruiting Fred Gordin 202-745-8301
Seattle King County Health Department *Recruiting*
Seattle, Washington, 98104
United States
Recruiting Charles Nolan 206-731-4582
Central Arkansas Veterans Health System *Recruiting*
Little Rock, Arkansas, 72205
United States
Recruiting Rebecca Martin 501-257-5778
University of British Columbia *Recruiting*
Vancouver, British Columbia, Canada V5Z 4R4
Canada
Recruiting J FitzGerald 604-660-6127
Chicago VA Medical Center (Lakeside) *Recruiting*
Chicago, Illinois, 60611
United States
Recruiting Mondira Bhattacharya 312-469-3847
Boston Medical Center *Recruiting*
Boston, Massachusetts, 02118
United States
Recruiting John Bernardo 617-638-4860
Nashville VA Medical Center *Recruiting*
Nashville, Tennessee, 37212-2637
United States
Recruiting Doug Kernodle 615-327-4751
Harlem Hospital Center *Recruiting*
New York City, New York, 10037
United States
Recruiting Wafaa El-Sadr 212-939-2936
New Jersey Medical School *Recruiting*
Newark, New Jersey, 07107-3001
United States
Recruiting Bonita Mangura 973-972-3270
Johns Hopkins University School of Medicine *Recruiting*
Baltimore, Maryland, 21287-0003
United States
Recruiting Richard Chaisson 410-955-1754
University of California, San Francisco *Recruiting*
San Francisco, California, 94110
United States
Recruiting Charles Daley 415-206-4694
Hines VA Medical Center *Recruiting*
Hines, Illinois, 60141
United States
Recruiting Constance Pachucki 708-202-2763
University of Manitoba *Recruiting*
Winnipeg, Manitoba, CANADA R3A 1R8
Canada
Recruiting Earl Hershfield 204-787-2977
Additional Information:
Study ID Numbers: 3041; TBTC Study 26
Study Start Date:
Record last reviewed: March 2002
Additional information available at: clinicaltrials.gov
Clinicaltrials.gov Reference link: NCT00023452
Other Tuberculosis Studies:
1. Prophylaxis Against Tuberculosis (TB) in Patients With Human Immunodeficiency Virus (HIV) Infection and Confirmed Latent Tuberculous Infection
2. Daily Isoniazid to Prevent Tuberculosis in Infants Born to Mothers with HIV
3. Prophylaxis Against Tuberculosis (TB) in Patients With Human Immunodeficiency Virus (HIV) Infection and Suspected Latent Tuberculous Infection
4. Moxifloxacin As Part of a Multi-Drug Regimen For Tuberculosis
5. Metabolism of Antituberculosis Drugs in HIV-Infected Persons With Tuberculosis
Related Studies:
Other Tuberculosis Clinical Trials
Other British Columbia Clinical Trials
Other Vancouver Clinical Trials
A Study of the Effectiveness and Tolerability of Weekly Rifapentine/Isoniazid for Three Months Versus Daily Isoniazid for Nine Months for the Treatment of Latent Tuberculosis Infection
|
|
|
|
|
|
|
|